Sam Brusco, Associate Editor11.21.23
LivaNova has disclosed that portions of its information technology systems were disrupted as a result of a cybersecurity incident.
The company, which makes therapeutic devices for the head and heart, said it has initiated an investigation into the incident with external cybersecurity experts and is working with law enforcement.
However, LivaNova also advised in a regulatory filing that the incident has caused and will keep causing disruption to parts of its operations. The company has already taken some of its systems offline to remediate the issue.
LivaNova admitted it couldn’t determine, at this time, the extent of the cybersecurity event’s impact on its business, results of operations, cash flows, or financial condition.
The company recently reported Q2 revenue of $286.1 million—12.1% over the prior-year period on a constant-currency basis. LivaNova changed its full-year 2023 guidance to grow between 9-11% as a result, and changed adjusted diluted earnings per share to $2.60-$2.80.
Last month, the firm earned U.S. Food and Drug Administration (FDA) 510(k) clearance for Essenz, its newest heart-lung machine. Essenz was also awarded approval from Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
The company, which makes therapeutic devices for the head and heart, said it has initiated an investigation into the incident with external cybersecurity experts and is working with law enforcement.
However, LivaNova also advised in a regulatory filing that the incident has caused and will keep causing disruption to parts of its operations. The company has already taken some of its systems offline to remediate the issue.
LivaNova admitted it couldn’t determine, at this time, the extent of the cybersecurity event’s impact on its business, results of operations, cash flows, or financial condition.
The company recently reported Q2 revenue of $286.1 million—12.1% over the prior-year period on a constant-currency basis. LivaNova changed its full-year 2023 guidance to grow between 9-11% as a result, and changed adjusted diluted earnings per share to $2.60-$2.80.
Last month, the firm earned U.S. Food and Drug Administration (FDA) 510(k) clearance for Essenz, its newest heart-lung machine. Essenz was also awarded approval from Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
Learn more about how cybersecurity issues could threaten the medical device industry here!